Jan 28, 2026 8:00am EST Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Jan 08, 2026 8:00am EST Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Dec 09, 2025 8:00am EST Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Dec 02, 2025 8:00am EST Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Nov 20, 2025 8:00am EST Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Nov 17, 2025 8:05am EST Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs